
Active Biotech Q4 2023 - Three Externally Funded Trials in 2024

Redeye provides its view of Active Biotech's fourth quarter report of 2023 and updates its base case.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Active Biotech Q4 2023 - Three Externally Funded Trials in 2024](#)